PT - JOURNAL ARTICLE AU - Djunadi, Trie Arni AU - Oh, Youjin AU - Lee, Jeeyeon AU - Yu, Jisang AU - Chung, Liam Il-Young AU - Lee, Yeunho AU - Kim, Leeseul AU - Hong, Timothy AU - Lee, Soowon AU - Shah, Zunairah AU - Park, Joo Hee AU - Yoon, Sung Mi AU - Chae, Young Kwang TI - Redefining Clinical Hyperprogression: the Incidence, Clinical Implications, and Risk Factors of Hyperprogression in Non-Small Cell Lung Cancer Treated with Immunotherapy AID - 10.1101/2024.01.04.23300116 DP - 2024 Jan 01 TA - medRxiv PG - 2024.01.04.23300116 4099 - http://medrxiv.org/content/early/2024/01/05/2024.01.04.23300116.short 4100 - http://medrxiv.org/content/early/2024/01/05/2024.01.04.23300116.full AB - Introduction Immune checkpoint inhibitors (ICIs) may be associated with hyperprogressive disease (HPD). However, there is currently no standardized definition of HPD, with its risk factors and clinical implications remaining unclear. We investigated HPD in lung cancer patients undergoing immunotherapy, aiming to redefine HPD, identify risk factors, and assess its impact on survival.Methods Clinical and radiologic data from 121 non-small cell lung cancer (NSCLC) patients with 136 immunotherapy cases were reviewed retrospectively. Three HPD definitions (Champiat et al., HPDc; Saâda-Bouzid et al., HPDs; and Ferrara et al., HPDf) were employed. Additionally, all new measurable lesions on the post-treatment CT scan were incorporated in measuring the sum of longest diameters (SLD) to define modified HPD (mHPD).Results Among the 121 patients, 4 (3.3%) had HPDc, 11 (9.1%) had HPDs, and none had HPDf. Adding all new measurable lesions increased HPD incidence by 5%–10% across definitions. Multivariate analysis revealed significantly lower progression-free survival (PFS) and overall survival (OS) for patients with HPDc (HR 5.25, p=0.001; HR 3.75, p=0.015) and HPDs (HR 3.74, p<0.001; HR 3.46, p<0.001) compared to those without. Patients with mHPD showed similarly poor survival outcomes as HPD patients. Liver metastasis at diagnosis was associated with HPDs, and a high tumor burden correlated with HPDc.Conclusions The incidence and risk factors of HPD varied with different definitions, but mHPD identified more cases with poor outcomes. This comprehensive approach may enhance the identification of at-risk patients and lead to a better understanding of HPD in lung cancer during immunotherapy.Competing Interest StatementYoung Kwang Chae COI Research Grant: Abbvie, BMS, Biodesix, Freenome, Predicine Honoraria/Advisory Boards: Roche/Genentech, AstraZeneca, Foundation Medicine, Neogenomics, Guardant Health, Boehringher Ingelheim, Biodesix, Immuneoncia, Lilly Oncology, Merck, Takeda, Lunit, Jazz Pharmaceutical, Tempus, BMS, Regeneron, NeoImmunTech, Esai Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Institutional Review Board Committee of Northwestern University (STU00207117).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present work are contained in the manuscriptHPDhyperprogressive diseaseICIimmune checkpoint inhibitorsNSCLCnon-small cell lung cancerSLDsum of longest diametersTGKtumor growth kineticsCTComputed tomographyTGRtumor growth rateHPDcdefinitions suggested by Champiat et al.HPDsdefinitions suggested by Saâda-Bouzid et al.HPDfdefinitions suggested by Ferrara et al.PFSprogression-free survivalOSoverall survivalmHPDmodified HPDPSECOG performance statusPD-L1programmed death L1TMBtumor mutational burdenNLRneutrophil-to-lymphocyte ratioNOSnot otherwise specifiedirRCimmune-related response criteriaCRcomplete responsePRpartial responseSDstable diseasePDprogressive diseaseCIconfidence intervalNGSnext-generation sequencingINFγinterferon-gammaFGF2fibroblast growth factor 2